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Abstract
Breast cancer is the most common malignancy in women and the appearance of distant metastases produces the death in 98% of cases. The
retinoic acid receptor b (RARb) is not expressed in 50% of invasive breast carcinoma compared with normal tissue and it has been associated
with lymph node metastasis. Our hypothesis is that RARb protein participates in the metastatic process. T47D and MCF7 breast cancer cell lines
were used to perform viability assay, immunobloting, migration assays, RNA interference and immunofluorescence. Administration of retinoic
acid (RA) in breast cancer cells induced RARb gene expression that was greatest after 72 hrs with a concentration 1 lM. High concentrations
of RA increased the expression of RARb causing an inhibition of the 60% in cell migration and significantly decreased the expression of migra-
tion-related proteins [moesin, c-Src and focal adhesion kinase (FAK)]. The treatment with RARa and RARc agonists did not affect the cell
migration. On the contrary, the addition of the selective retinoid RARb-agonist (BMS453) significantly reduced cell migration comparable to RA
inhibition. When RARb gene silencing was performed, the RA failed to significantly inhibit migration and resulted ineffective to reduce moesin,
c-Src and FAK expressions. RARb is necessary to inhibit migration induced by RA in breast cancer cells modulating the expression of proteins
involved in cell migration.
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Introduction
Breast cancer is the most common malignancy in women, with
~1.38 million new patients and 459,000 deaths/year worldwide
(http://globocan.iarc.fr/). Despite improvements in early diagnosis
and surgical and adjuvant systemic therapies for breast cancer, the
mortality rate has remained high. It is therefore necessary to continue
searching for novel approaches to breast cancer prevention, early
detection and treatment.
Although at early stages breast cancer could be a well-curable dis-
ease, when metastasis occurs, the prognosis is severe. Metastasis
constitutes the final step of the neoplasic progression and it became
in the primary cause of death from solid tumours [1]. Therefore, the
detailed knowledge of the molecular actions linked to the metastasis
process is critical for the development of novel therapeutic strategies
in oncology.
Retinoids are a family of signalling molecules chemically related
to vitamin A (retinol). At present, little is known about the possible
effects of retinoids, specifically, the retinoic acid (RA) role in breast
cancer progression and metastasis. Retinoic acid, an active metabo-
lite of vitamin A, plays essential roles in development, differentiation,
cell growth and cellular homoeostasis [2, 3]. All-trans, 9-cis, and 13-
cis-RA are three stereoisomers of the RA [4]. They exert their meta-
bolic effects mainly through the nuclear receptors: retinoic acid
receptors (RAR) and the retinoic X receptors, both belong to the
nuclear receptors superfamily [5].
The RARb has become a particularly interesting target in cancer
research. During cancer progression, RARb gene deletion or
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promoter hypermethylation frequently occurs. It has been suggested
that RARb re-expression can restore RA-mediated growth control,
indicating that the anticancer action of retinoids is mediated by RARb
[6–8]. Consequently, RARb has been proposed as a tumour suppres-
sor. However, the mechanism underlying its antitumour action has
not yet revealed.
The RARb promoter contains a high affinity RA-responsive ele-
ment RARE [5, 9, 10], which is associated with the transcriptional
activation of RARb by RA in a variety of cells [5]. It has been
observed an important reduction in RARb mRNA expression in differ-
ent types of human carcinomas including breast carcinoma [11–13].
Loss of RARb gene expression has been reported in ~50% of
invasive breast carcinomas and it has been proposed as an essential
player in the conversion of non-invasive breast cancer into invasive
disease [13–16]. The RARb tumour suppressor gene is the only RAR
whose levels decrease drastically in many tumour types, but when
RARb get re-expressed the clinical response might be improved [17].
Genetic and epigenetic alterations may originate a progressive
decrease in RARb mRNA expression and the lack of RA response dur-
ing breast carcinogenesis [12, 13]. Recent studies have found that
lack of RARb is more often because of DNA methylation affecting the
RARb promoter [6, 8, 18]. The high frequency of hypermethylation in
the RARb promoter also suggests that epigenetical changes may confer
a survival advantage to the disseminated cells at the distant site [19].
Recently, our laboratory, in accordance with other authors, has
shown that RARb methylation in primary breast tumours correlated
with lymph node invasion and metastasis [20]. The metastatic pro-
cess requires the acquisition of invasive properties such as motility,
invasion and remodelling of the extracellular matrix (ECM). A key reg-
ulator of ECM signals is the actin-binding protein moesin, which
belongs to the ezrin/radixin/moesin (ERM) family. Activated moesin
triggers the de-polymerization of actin fibres and the re-assembly of
microfilaments towards the cell membrane edge, leading to the for-
mation of cortical actin complexes and specialized cell membrane
structures implicated in the generation of the cellular locomotive force
[21]. Interestingly, ERM proteins have been recently reported as key
regulators of metastasis in aggressive cancers [22, 23]. Another ECM
controller is the focal adhesion kinase (FAK), a non-receptor protein
tyrosine kinase involved in cell attachment, migration, invasion, cru-
cial steps for cancer development and metastasis [24, 25]. Focal
adhesion kinase overexpression has been described in human can-
cers and is related to invasive potential of tumour cells and poor
prognosis [24, 26, 27]. It has been shown that FAK suppression is
associated with decreased mobility and metastastic capacity in breast
cancer cells [28]. Focal adhesion kinase is activated by c-Src, a non-
receptor tyrosine kinase that recruited FAK to the c-Src complex [29].
In addition, the activation of c-Src has been significantly associated
with tumour progression and aggressive features [30, 31]. Activated
FAK–Src complex mediates the phosphorylation of multiple adhesion
components involved in the dynamic regulation of cell motility.
The purpose of our study was to investigate the effects of RA on
human breast cancer cells migration, underlying molecular mecha-
nisms involved and the possible roles of RARb. To this aim, we stud-
ied the consequences of RA treatment on the expression of moesin,
c-Src and FAK and actin remodelling in breast cancer cells.
Materials and methods
Cell cultures and treatments
The human breast carcinoma cell lines T47D and MCF7 were obtained
from the American Type Culture Collection (Rockville, MD, USA). T47D
and MCF7 cells were routinely grown in RPMI 1640 supplemented with
L-glutamine (2 mM) and 10% foetal bovine serum. All-trans-RA was
obtained from Sigma Chemical Co. (St. Louis, MO, USA). Retinoic acid
stock solution was dissolved in dimethyl sulfoxide (DMSO) at a concen-
tration of 102 M and maintained at 20°C, protected from light and in
an inert atmosphere. The synthetic agonist retinoids, selective for RARa
(BMS753), RARb (BMS453) and RARc (BMS961), and synthetic antag-
onist retinoids selective for RARa (BMS195614; Tocris Bioscience,
Bristol, UK) were kindly provided by Dr. Hinrich Gronemeyer (IGBMC,
Illkirch, France). Agonist and antagonist retinoids were diluted in ethanol
and added to the culture medium to give a final concentration of
106 M. In control cultures, the DMSO or ethanol vehicle was added at
the same final dilution. All experiments with retinoids were performed in
reduced room light.
Viability assay
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-difeniltetrazol] (Sigma Aldrich,
St. Louis, MO, USA) was dissolved at a concentration of 5 mg/ml in
RPMI culture medium. The working solution was 0.1 mg/ml MTT. Cell
lines were seeded into 96 well plates at a density of 13,000 cells/well.
24 hrs later, the RA dose-dependency treatment (107/105 M) was
performed. After 72 hrs, the medium was removed and the cells were
incubated with 100 ll MTT/well (0.5 mg/ml) for 3–4 hrs. MTT was
removed and the formazan crystals rings were dissolved in 100 ll of
DMSO. Absorbance at 570 nm was measured by using a microplate
reader (MULTISKAN EX; Thermo Scientific, Lafayette, CO, USA).
Cell migration assays (wound healing assay)
Scratch wound assay was conducted to assess the influence of RA cell
migration. T47D and MCF7 cells were seeded in six well plates and incu-
bated until 70–80% confluence. Wounds were made in the monolayers by
scratching the surface with a pipette tip (1000 ll) as uniformly and
straight as possible. Then, the cells were washed and 2.0 ml of RPMI
containing steroid-deprived fetal bovine serum were added. Cytosine b-D-
arabinofuranoside hydrochloride (Sigma-Aldrich; 10 lM), a selective
inhibitor of DNA synthesis which does not inhibit RNA synthesis, was
used 1 hr before the test substance was added. Cell migration
was monitored for 72 hrs. Every 12 hrs, fresh medium and treatment
was replaced. Digital images from cells were taken and the distance of
migration was then analysed by phase-contrast microscopy.
Immunoblotting
Cell lysates were separated by SDS-PAGE. Antibodies used were: Mouse
Anti-FAK (610088) and Mouse Anti-moesin (clone 38, 610401; BD
Transduction Laboratories, Milano, Italy), Mouse Anti-c-Src (sc-5266)
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and Rabbit Anti-RARb (C-19): sc-552 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Primary and secondary antibodies were incubated with
the membranes by using standard techniques. Immunodetection was
accomplished by using enhanced chemiluminescence. The images were
captured by using ChemiDocTM XRS+ System with Image LabTM Software
#170-8265 (Bio-Rad, Hercules, CA, USA).
Transfection experiments
The synthetic small interfering RNA for RARb: sc-29466 was from
Santa Cruz Biotechnology and control siRNA (D-001810-01-05) was
obtained from Dharmacon (Thermo Fisher Scientific Inc.). T47D and
MCF7 cells (60–70% confluent) were transfected with 50–75 nM of tar-
get siRNA or control siRNA by using Lipofectamine (Invitrogen, Carls-
bad, CA, USA). The cells were treated 24 hrs after siRNA transfection.
Transfection efficiency was checked for expression of RARb by imuno-
blotting and it was optimal at 48 hr.
Cell adhesion assay
Five hundred thousand cells per well were seeded into 6-well plates on
coverslips previously coated with 1% sterile gelatin (Sigma-Aldrich) and
exposed to different treatments. The cells were incubated at 37°C (in
tissue culture incubator) and after 1 hr, the plates were shaken for
1 min. at 150 r.p.m. and washed with PBS to remove any non-adherent
cells. The attached cells were fixed with 4% formaldehyde and stained
with Giemsa. Cells attached images were captured and counted by
using a Nikon Eclipse E200 microscope coupled to a high-resolution
590CU 5.0M CCD digital camera.
Immunofluorescence
T47D and MCF7 cells were grown on coverslips and exposed to treat-
ments. Cells were fixed with 4% paraformaldehyde for 30 min. and per-
meabilized with 0.1% Triton for 5 min. Blocking step was performed
with 3% bovine serum albumin solution for 30 min. at room tempera-
ture. Cells were incubated with the first antibody against moesin (clone
38) overnight at 4°C. After washing, the cells were incubated with goat
antimouse IgG-Alexa Fluor 488 (A-11001; Invitrogen) for 1 hr at room
temperature. The cells were washed and then stained with Texas Red-
phalloidin (Sigma-Aldrich) to reveal actin and the nuclei counterstained
with 40-6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). The cover-
slips cells were mounted with Vectashield mounting media (Vector Lab-
oratories, Burlingame, CA, USA). Immunofluorescence images were
captured by using a Nikon Eclipse E200 microscope (Tokyo, Japan)
coupled to a high-resolution 590CU 5.0M CCD digital camera.
Evaluation of cellular morphology
Immunofluorescence images stained with Texas red-phalloidin (actin)
were used to quantify the effects, of cells with a static and a migratory
phenotype. Cells simultaneously showing loss of stress fibres, progres-
sive localization of actin towards the edge of the cell membrane, and
presence of numerous stress fibre arcs were considered as having a
migratory phenotype [32]. Conversely, a static phenotype was charac-
terized by actin fibres arranged longitudinally through the major axis of
the cell shape [32].
Statistical analysis
D’Agostino & Pearson omnibus normality test was used to determine
whether the samples have normal distribution. Statistical analysis of the
data was performed with one-way ANOVA followed by Turkey-Kramer
Multiple-Comparisons test or the non-parametric Kruskal–Wallis test
(GraphPad PRISM program version 5.0, San Diego, CA, USA). P < 0.05
was considered as statistically significant. All values were expressed as
mean  SD.
Results
Effects of RA on breast cancer cells viability
Retinoids are known to inhibit the growth of breast cancer cells [2,
11]. However, the MTT assay showed that 72 hrs of RA treatment at
increasing concentrations (107–105 M) did not affect T47D and
MCF7 cells viability, but at the highest concentrations (105 M) in
MCF7 cells, the viability decreased 20% compared with untreated
(control) cells (Fig. 1A and B).
A B
Fig. 1 (A and B) The cellular lines MCF7 and T47D were seeded at 13,000 cells per well and treated with RA (107/105 M) for 3 days. The results
were expressed as percentage (%) of survival cells. All data shown were representative of three independent experiments. Error bars indicate stan-
dard deviations. *P < 0.05 versus Con.
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RA reduces MCF7 and T47D cells migration
The effect of RA on breast cancer cell migration was then tested in a
dose–response experiment. To distinguish cell migration from cell
proliferation, Cytosine-b-D-arabinofuranoside hydrochloride (10 lM),
a selective inhibitor of DNA strand separation that does not block
RNA synthesis, was used to arrest cell proliferation. After partially
scraping out MCF7 cells from the cell culture dish, we monitored the
movement of the remaining cells for the following 72 hrs. After
72 hrs, 106 and 105 M of RA significantly inhibited the migration
of MCF7 cells towards the scraped area ‘the wound healing’ compared
with control untreated cells (Fig. 2A and B). It is important to note
that the 60% of cell migration inhibition started from RA 106 M, but
at the same concentration the cell viability was not affected (Figs 1A
and 2A, B). Similar results were obtained in T47D cellular line (data
not shown).
The synthetic retinoid RARb agonist, BMS 453,
inhibits breast cancer cells migration
To determine which subtype of RAR is involved in RA-induced migra-
tion inhibition, we tested the effects of selective synthetic retinoid
agonists, for RARa (BMS753), RARb (BMS453) and RARc
(BMS961), and the RARa-selective antagonist (BMS195614).
Treatment with RA 106 M for 72 hrs significantly reduced T47D
breast cancer cells migration (Fig. 2C and D). Retinoic acid receptor
a-selective antagonist (BMS195614) in combination with RA did not
affect the cell movement, suggesting that RARa receptor is not
required for RA effects on cell migration. The RARb-selective agonist
(BMS453), but not RARa- or RARc-selective agonists (BMS753 and
BMS961, respectively), significantly reduced the cell migration to lev-
els comparable to inhibition by RA, indicating that RARb is involved
in RA-inhibited cell migration (Fig. 2C and D). Similar results were
obtained in MCF7 cellular line (data not shown).
RARb protein expression is regulated by AR in
breast cancer cells lines
The expression of RARb protein varies among breast cancer cell
lines. Zhang et al. did not detect RARb expression in five breast can-
cer cell lines and showed that the treatment with RA could induce its
expression [33]. We have evaluated the RARb protein expression in
three breast cancer cells lines under basal conditions (MDA-MB231,
T47D and MCF7). We verified that RARb protein expression was
A B
C D
Fig. 2 (A) MCF7 cells were treated with retinoic acid (RA) in different concentrations (107/105 M) and cell migration was imaged after 72 hrs. (B)
Gap closure was quantified with the use of NIH image J software. *P < 0.05 versus Con. (C) T47D cells were treated with RA (106 M) and the
synthetic agonist retinoids, selective for RARa Agonist (BMS753), RARb Agonist (BMS453) and RARc Agonist (BMS961), and the synthetic antago-
nist retinoids selective for RARa (BMS195614) plus RA (106 M). All retinoids were incubated at 106 M for 72 hrs. Cell migration was imaged
after 72 hrs. (D) Gap closure was quantified with the use of NIH image J software. *P < 0.05 versus Con. These experiments were performed in
triplicates and representative images are shown.
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higher in T47D cells compared with MDA-MB231 and MCF7 cells
(Fig. 3A). This result is in accordance with other authors who have
shown that RARb gene expression may be lost by hypermethylation
in breast cancer cells lines such as MDA-MB231 or MCF7 cells [6].
Next, we investigated the expression of RARb in MCF7 cells after
a RA dose-dependent treatment. It has been reported that RARb is
weakly expressed in MCF7 cells but it can be induced by RA treatment
[6]. Our results demonstrate that RA administration on MCF7 cells
can induce RARb protein expression with a peak at 106 M after
72 hrs (Fig. 3B and C), which is consistent with the kinetics of
RA-induced migration inhibition.
RA reduces the expression of moesin, c-Src and
FAK, which correlates with its migration-
inhibitory effect
Based on our previous findings in which the actin-regulatory protein
moesin and the kinases c-Src and FAK resulted to be essential pro-
teins for the migration induced by different hormones [34–36], we
have investigated if these proteins could be involved in the biological
activities of RA resulting in reduced breast cancer cells migration.
Time-dependent treatment (24–72 hr) with RA 106 M significantly
reduced the expression of moesin, c-Src and FAK (Fig. 3C). Interest-
ingly, the expression levels of moesin, FAK and c-Src in these cells
were inversely correlated with those of RARb (Fig. 3C).
RA fails to impaired cellular migration when
RARb is silenced
We next treated MCF7 cells with RA (106 M/72 hr) and another
group was first transfected with a specific RARb siRNA and then
exposed to or not with RA (106 M/72 hr). After performing a cell
migration assay, we found that RA was able to significantly decrease
cell migration, but failed to inhibit migration in cells transfected with
RARb siRNA, indicating that the inhibition of cell migration by RA is
mediated by the RARb pathway (Fig. 4A and B).
To demonstrate if RARb mediates RA effects on cell movement,
we have studied the expression of moesin, c-Src and FAK proteins in
MCF7 cells treated with RA after RARb silencing. Therefore, RARb
silencing impaired the reduction in these proteins by RA indicating a
RARb-dependent behaviour. In other words, RA reduced the expres-
sion of these proteins through RARb (Fig. 4C).
RA reduces migration and adhesion in T47D
cells
The treatment with RA (106 M/72 hr) caused 50% inhibition of cell
migration in T47D cells (Fig. 5A and B). Retinoic acid failed to inhibit
the cell migration after RARb silencing, suggesting that RA could
suppress the cell migration through RARb (Fig. 5A and B). Further-
more, untreated cells transfected with a control siRNA showed a
lower cell migration than RARb-silenced cells (Fig. 5A and B).
On the contrary to the expected, RARb-siRNA transfected T47D
cells showed a similar decrease in moesin, FAK and c-Src expres-
sions after treatment with RA (Fig. 5C).
In addition to reduce T47D cells migration, the treatment with RA
(105 M/72 hr) significantly inhibited T47D cell adhesion to gelatin
(Fig. 5D).
RA induces a static phenotype of migration
through inhibition of Moesin
To better understand the dynamics of breast cancer cells migration
and the different behaviour observed between untreated and RA trea-
ted cells, we next investigated changes in the cytoskeleton organiza-
tion induced by RA treatments. MCF7 and T47D cells non transfected/
A
B
C
Fig. 3 (A) Western blot analysis for RARb protein was performed in 30 lg of total lysate of untreated MDA-MB231, T47D and MCF7 breast cancer
cells. (B) Western blots show total cell amount of RARb in MCF7 treated with different concentrations of retinoic acid (RA; 108/105 M) for
48 hrs. (C) MCF7 breast cancer cells were treated with RA (106 M) for 24, 48, 72 hrs and the RARb, FAK, moesin, and c-Src expression are
shown. Actin expression is shown in the lower boxes as loading control. The experiments were repeated three times with consistent results and rep-
resentative images are shown. Densitometric quantifications of all the blots (including those not shown) were performed and the relative
mean  SD of each condition are presented in graph as supplemental data online Fig. S1A–C.
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transfected with siRNA RARb were exposed to RA (106 M/72 hr).
We have examined through inmunofluorescence experiment the
expression and localization of the modulator protein moesin with
Alexa fluor 488 (green) and actin fibres with the specific marker Texas
red-phalloidin (red). In control cells (without treatment), actin fila-
ments arranged longitudinally along the major axis (Fig. 6A and B)
A
C
B
Fig. 4MCF7 cells were exposed to retinoic
acid (RA; 106 M/72 hr) and another
group was first transfected with a specific
RARb siRNA and then treated or not with
RA (106 M/72 hr). (A) Cell migration
was imaged after 72 hrs. (B) Gap closure
was quantified with the use of NIH image
J software. *P < 0.05 versus Con. (C)
Western blot analysis for RARb, FAK,
moesin and c-Src. Actin expression is
shown in the lower boxes as loading con-
trol. These experiments were performed in
triplicates and representative images are
shown. Densitometric quantifications of all
the blots (including those not shown)
were performed and the relative
mean  SD of each condition are pre-
sented in graph as supplemental data
online Fig. S2.
A B
C D
Fig. 5 T47D cells were exposed to retinoic acid (RA; 106 M/72 hr) and another group was first transfected with a control siRNA or specific RARb
siRNA and then treated or not with RA (106 M/72 hr). (A) Cell migration was imaged after 72 hrs. (B) Gap closure was quantified with the use of
NIH image J software. *P < 0.05 versus Con. (C) Western blot analysis for RARb, FAK, moesin, c-Src and Actin as loading control was performed.
(D) Representative images of T47D cell adhesion to gelatin after RA treatment (106/105 M) for 72 hrs are shown. These experiments were per-
formed in triplicates and representative images are shown. Densitometric quantifications of all the blots (including those not shown) were performed
and the relative mean  SD of each condition are presented in graph as supplemental data online Fig. S3.
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and moesin showed a diffuse distribution throughout the cytoplasm
(Fig. 6A and B). The treatment with RA significantly reduced the
expression of moesin, which changed its spatial organization, show-
ing an increment of stress fibres and a progressive localization of the
protein towards the nucleus. At this localization is difficult for moesin
to form cortical actin complexes, moesin aggregates or specialized
cell membrane structures, which are present in the cell membrane to
induce cell motility (Fig. 6A and B).
When the cells were transfected with the specific RARb siRNA,
RA failed to reduce moesin expression and was not effective to induce
moesin re-distribution (Fig. 6A and B).
Furthermore, after 72 hrs of RA 106 M incubation most of MCF7
and T47D cells showed a static phenotype (Fig. 7A). The static phe-
notype is generally characterized by numerous actin fibres longitudi-
nally arranged through the major axis of the cell shape. In contrast,
the migratory phenotype exhibits loss of stress fibres, progressive
localization of F-actin towards the edge of the cell membrane, and
numerous stress fibres arcs (Fig. 7A). Thus, after 72 hrs of RA incu-
bation, a significant difference in the number of cells with a migratory
phenotype was observed between controls and RA treated cells.
Moreover, this inhibitory effect was extremely limited in the RARb
down-regulated group (Fig. 7A), determining that RARb mediates the
effect of RA on moesin down regulation and cellular localization.
Discussion
Retinoids have long been investigated in preclinical models, and clini-
cal data have already supported the potential of these compounds in
cancer prevention and treatment [37–39].
A
B
Fig. 6 (A and B) MCF7 and T47D cells
were exposed to retinoic acid (RA;
106 M/72 hr) and another group was
first transfected with a specific RARb
siRNA and then treated or not with RA
(106 M/72 hr). Then the cells were
stained with anti-moesin (clone 38) linked
to Alexa Fluor 488 (green), actin was
stained with phalloidin linked to Texas
Red (red) and nuclei were counterstained
with DAPI (blue). All the experiments were
repeated three times with consistent
results, and the representative images are
shown. The microphotographs were taken
with a 100 9 objective.
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Retinoic acid is being increasingly included in both chemopreven-
tive and therapeutic schemes for various tumour diseases including
breast cancer [39–41]. In general, RA is believed to inhibit carcino-
genesis by blocking the promotion of initiated or transformed cells by
three mechanisms: induction of apoptosis, arrest of tumour growth
and/or differentiation of cancer cells [41]. Growth inhibition of breast
cancer cells by RA has been associated with the induction of RARb,
which may act as a tumour suppressor and appears to be down-regu-
lated in breast cancer cells and, conversely, up-regulated in normal
mammary epithelial cells [33].
Several studies have also reported that RA may inhibit invasion
and metastasis in diverse types of cancer such as breast [42] and
colon cancer cells [43]. However, the mechanism by which RA blocks
the late stages of carcinogenesis is largely unknown. In addition, limi-
tations in the successful of prevention and treatment of solid tumours
with retinoids may be related to the epigenetic silencing of RARb [4].
The multifaceted approach of this study was an attempt to provide
a comprehensive analysis of the RA effects on the migration capabil-
ity by using two human breast cancer cell lines. We have demon-
strated the ability of RA to inhibit breast cancer cell migration in a
dose- and time-dependent manner; others studies using various cell
lines also demonstrated a similar effect [44–47]. In agreement with
other authors, we have demonstrated the cellular motility inhibition
by RA in breast cancer cells in absence of growth inhibition [48]. The
possible mechanisms implicated in the RA anti-migratory effect
were further investigated, and our data showed that RA treatment
up-regulates RARb expression and down-regulates moesin, FAK, and
c-Src (proteins related to migration) expression in MCF7 cells (which
have very low RARb expression in basal conditions by promoter
methylation).
Numerous studies indicate that FAK could be an important player
in signalling cascades associated with cancer progression and metas-
tasis [49, 50]. Increased FAK expression has been correlated with
increased cell motility, invasiveness and proliferation [51, 52]. Moesin
has also been proposed as key regulator of metastasis in aggressive
cancers [22, 23]. Therefore, we hypothesize that RA reduces moesin,
FAK and c-Src expressions in breast carcinoma MCF7 cell lines by
RARb. In fact, RARb expression was induced by treatment with RA
and RARb silencing abolished the ability of RA to reduce the expres-
sion of moesin, FAK and c-Src in these cells. According to previous
reports, the anti-cancer potential of RA is mainly mediated by RARb
[7, 53] which increases the expression of the migration-related
protein E-cadherin [46].
In T47D cells, as in MCF7 cells, we observed that RA reduced sig-
nificantly cell migration (55%) but this reduction only represented
20–30%, when RARb was silenced. Contrary to our expectations,
after RARb silencing, RA reduced moesin, c-Src and FAK expressions
but cells express a migratory phenotype in which moesin is localized
near the edge of the cell membrane forming specific cellular struc-
tures for migration (cortical actin complexes, pseudopodia, and mem-
brane ruffles). Therefore, in T47D cells, the effect of RA on cell
migration may be mediated not only by RARb but also by RARa and/
or RARc. On the other hand, we have kept in mind that moesin, c-Src
and FAK are three of the several proteins related to motility and that
RARb could be involved in the modulation of one or more of these
proteins (talin, vinculin, paxilin and/or contactin).
In cancer cells with a down-regulated RARb expression, RA
resulted ineffective to reduce cellular migration, suggesting that
tumour cells could silence RARb to facilitate the escape of the
tumour triggering the metastatic process. This is the first time
A
B
Fig. 7 (A) Immunofluorescence images of
MCF7 and T47D cells stained with Texas
Red-phalloidin (actin) were used to quan-
tify the effects, of cells with a static and a
migratory phenotype. The results were
expressed as percentage (%) of Cells with
Migratory Phenotype. (B) Representative
images of Static and Migratory Phenotype
of T47D cells are shown. All the experi-
ments were repeated three times with
consistent results, and the representative
images are shown. The microphotographs
were taken with a 100 9 objective.
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that silencing of RARb was associated with cell migration, which
may contributes to its antitumour activity. In agreement with other
research groups, we consider that RARb promoter hypermethyla-
tion may confer a survival advantage to the disseminated cells at
the distant site [19].
Some authors have demonstrated that RA and other biologically
active retinoids inhibit cellular migration in several cell lines such as
human colon carcinoma cells [46], and human breast cancer MCF7
and MDA-MB-231 cells [54, 55]. Dutta et al. demonstrated that RA
treatment caused a significant decrease in FAK expression in MCF7
cells and they suggest that it may contribute to the cell motility
decreased [54]. Furthermore, in MDA-MB-231 cells, the same authors
demonstrate that RA enters into the nucleus and regulates various
signalling pathways including Integrin, FAK, ERK, PI-3K, NFkB and
down-regulates pro-MMP-9 activity as well as its expression. They
showed that the migration of MDA-MB-231 cells on fibronectin med-
ium is retarded in presence of RA [55]. However, these authors did
not explore which RA receptor subtype mediates the effects on cell
migration and motility.
Alterations in the adhesion and motility properties of neoplastic
cells may play a pivotal role in the development and progression of
the malignant phenotype in various tumour types. Invasion is a multi-
phase process constituted by different coordinated interdependent
steps, controlled by cross-talk mechanisms between cells and the
extracellular microenvironment [56].
We verified by indirect immunofluorescence staining, that RA
reduced the appearance of peculiar structures such as ruffles and
pseudopodia and it affected the cytoskeletal rearrangement through
reorganization of the stress fibres inhibiting the formation stress
fibres arcs and lamellipodia that frequently occur in moving cells.
Retinoic acid induced a static phenotype in MCF7 and T47D cells,
with actin fibres longitudinally arranged through the major axis of
the cell surface. Thus, after 72 hrs of RA incubation, a statistically
significant reduction in the number of cells with a migratory pheno-
type was observed. Moreover, this inhibitory effect was extremely
limited in RARb down-regulated group. Our results indicate that RA
may play a significant role in breast cancer development and pro-
gression modulating cellular migration and cytoskeletal reorganiza-
tion via RARb.
Chang et al. demonstrated that RA differentially regulates de novo
synthesis of various ECM proteins in cultured human retinal pigment
epithelial cells (RPE) [57]. The underlying mechanism may be, at least
in part, becuase of the suppressive effects of RA on integrin b3
expression. In conclusion, RA appears to have the ability to alter the
expression of ECM proteins, remodelling the cytoskeleton [57, 58].
Therefore, we speculate that RA could modify the breast cancer cells
phenotype from invasive to non-invasive. Du. et al. demonstrated that
after RA treatment, twenty genes which were correlated with migra-
tion of RPE cells were down-regulated, whereas another four genes
had been up-regulated [58]. They found that the expression of inte-
grin genes were down-regulated by RA. Integrins are proteins highly
related to FAK. The up-regulation of E-cadherin by RA prevents RPE
cell migration through maintaining cell and tissue cohesion. There-
fore, genes whose expressions are involved in motility may play an
important role in migration and invasion [58].
The strong antimetastatic effect of RA suggests the importance to
design treatments combining retinoids and other agents. Several reti-
noids are currently in clinical trials to treat or prevent breast cancer
progression. Retinoids are effective inhibitors of breast cancer cells at
the early stages of tumour progression, but their effectiveness dimin-
ishes when the tumours become more aggressive [59]. Therefore, to
develop rational retinoid-based therapy for breast cancer, it becomes
necessary to elucidate the molecular pathways activated by retinoids.
Retinoic acid receptor b expression deficiency and inadequate
responsiveness of retinoids via RARb may reduce the treatment effi-
cacy in patients with advanced breast tumours [59]. It is also becom-
ing increasingly obvious that RARb expression is lost early in
carcinogenesis and it is epigenetically silenced [6] in many solid
tumours, providing an opportunity for novel treatment strategies to
be investigated by using retinoids together with epigenetic modifiers
that promote re-expression of silenced genes. The limited treatment
success with retinoids observed to date in the prevention and treat-
ment of solid tumours may be related to the frequent epigenetic
silencing of RARb. Robust evaluation of RARb and downstream
genes may optimize the use of retinoids in solid tumours.
Conclusion
Our study demonstrates that high concentrations of RA induce RARb
expression which mediates cell migration and cell motility inhibition
in breast cancer cells. The results show the participation of RA in
some properties of cancer cells involved in the metastatic process,
like motility and adhesivity. More pharmacokinetic studies of retinoids
are needed to elucidate other biological effects of retinoids in human
tumour cells to design novel clinical trials for cancer therapy or strat-
egies to prevent the malignant transformation.
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cancer cells. (B) RARb in MCF7 cells treated with different concentra-
tions of RA (108/105 M) for 48 hr. (C) RARb, FAK, moesin, and
c-Src expression in MCF7 cells treated with RA (106 M) for 24, 48,
72 hr. and the are shown.
Figure S2 Densitometric quantification of western blot analysis for
RARb FAK, moesin and c-Src in MCF7 cells exposed to RA (106 M/
72 hr) or transfected with a specific RARb siRNA and then treated or
not with RA (106 M/72 hr).
Figure S3 Densitometric quantification of western blot for RARb,
FAK, moesin, c-Src in T47D cells exposed to RA (106 M/72 hr) or
transfected with a control siRNA or specific RARb siRNA and then
treated or not with RA (106 M/72 hr)
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